J&J recalls Procrit lot with cracked vials
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's Ortho Biotech division has recalled one manufacturing lot of its erythropoiesis-stimulating agent Procrit (epoetin-alfa) in the US owing to cracks in the necks of some vials. More than 44,000 vials in the affected lot were distributed between April 15th and July 17th. The company said it had not received any reports of adverse events or complaints, but cracked vials may lose their sterility and should not be used for subcutaneous or intravenous injection. The amount of Procrit being withdrawn represents a very small proportion of the total product in the distribution channel and J&J does not anticipate a supply disruption.
You may also be interested in...
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.
Eye On ODAC: Former Members, FDA’s Pazdur Talk Pre-Meeting Mindsets, Impact Of Sponsor’s Experts
Oncologic Drugs Advisory Committee reps and the Oncology Center of Excellence director go behind the scenes to discuss FDA interactions with panelists, how opinions can change during a meeting, and why the voting question is important.